MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DIVIS LABORATORIES - MYLAN (US)
DIVIS LABORATORIES vs MYLAN (US) - Comparison Results
DIVIS LABORATORIES Change
Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 DIVIS LABORATORIES  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DIVIS LABORATORIES Mar-19 |
MYLAN Dec-18 |
DIVIS LABORATORIES/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,639 | 3,474 | - | |
| Low | Rs | 1,115 | 1,912 | - | |
| Sales per share (Unadj.) | Rs | 186.3 | 1,598.5 | - | |
| Earnings per share (Unadj.) | Rs | 51.0 | 43.4 | - | |
| Cash flow per share (Unadj.) | Rs | 57.3 | 342.7 | - | |
| Dividends per share (Unadj.) | Rs | 16.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.2 | 0 | - | |
| Book value per share (Unadj.) | Rs | 261.8 | 1,729.3 | - | |
| Shares outstanding (eoy) | m | 265.47 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 7.4 | 1.7 | 438.7% | |
| Avg P/E ratio | x | 27.0 | 62.0 | 43.6% | |
| P/CF ratio (eoy) | x | 24.0 | 7.9 | 305.8% | |
| Price / Book Value ratio | x | 5.3 | 1.6 | 337.8% | |
| Dividend payout | % | 31.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 365,592 | 1,385,529 | 26.4% | |
| No. of employees | `000 | 11.8 | 35.0 | 33.8% | |
| Total wages/salary | Rs m | 5,423 | 0 | - | |
| Avg. sales/employee | Rs Th | 4,175.1 | 23,497.5 | 17.8% | |
| Avg. wages/employee | Rs Th | 457.7 | 0 | - | |
| Avg. net profit/employee | Rs Th | 1,141.8 | 638.1 | 179.0% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 49,463 | 822,412 | 6.0% | |
| Other income | Rs m | 1,556 | 0 | - | |
| Total revenues | Rs m | 51,019 | 822,412 | 6.2% | |
| Gross profit | Rs m | 18,718 | 212,810 | 8.8% | |
| Depreciation | Rs m | 1,689 | 153,988 | 1.1% | |
| Interest | Rs m | 35 | 39,555 | 0.1% | |
| Profit before tax | Rs m | 18,551 | 19,267 | 96.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 5,023 | -3,065 | -163.9% | |
| Profit after tax | Rs m | 13,527 | 22,332 | 60.6% | |
| Gross profit margin | % | 37.8 | 25.9 | 146.2% | |
| Effective tax rate | % | 27.1 | -15.9 | -170.2% | |
| Net profit margin | % | 27.3 | 2.7 | 1,007.2% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 46,501 | 459,234 | 10.1% | |
| Current liabilities | Rs m | 8,468 | 334,832 | 2.5% | |
| Net working cap to sales | % | 76.9 | 15.1 | 508.3% | |
| Current ratio | x | 5.5 | 1.4 | 400.4% | |
| Inventory Days | Days | 131 | 84 | 156.5% | |
| Debtors Days | Days | 86 | 93 | 92.0% | |
| Net fixed assets | Rs m | 25,797 | 159,534 | 16.2% | |
| Share capital | Rs m | 531 | 438 | 121.2% | |
| Net worth | Rs m | 69,493 | 889,699 | 7.8% | |
| Long term debt | Rs m | 0 | 960,271 | 0.0% | |
| Total assets | Rs m | 80,383 | 2,386,519 | 3.4% | |
| Interest coverage | x | 531.0 | 1.5 | 35,708.8% | |
| Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
| Sales to assets ratio | x | 0.6 | 0.3 | 178.6% | |
| Return on assets | % | 16.9 | 2.6 | 650.6% | |
| Return on equity | % | 19.5 | 2.5 | 775.5% | |
| Return on capital | % | 26.7 | 3.2 | 841.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,543 | 170,897 | 5.6% | |
| From Investments | Rs m | -6,854 | -88,335 | 7.8% | |
| From Financial Activity | Rs m | -2,459 | -79,614 | 3.1% | |
| Net Cashflow | Rs m | 230 | 1,416 | 16.2% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 72.98 Rs / USD
Compare DIVIS LABORATORIES With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare DIVIS LABORATORIES With: PFIZER ABBOTT INDIA FDC NATCO PHARMA SUN PHARMA
Today's Market
Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)
Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.
Related Views On News
DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)
Aug 10, 2020 | Updated on Aug 10, 2020For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)
Jun 8, 2020 | Updated on Jun 8, 2020For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.
DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)
Oct 10, 2019 | Updated on Oct 10, 2019Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.
More Views on NewsMost Popular
Time to Book Profits in Pharma Stocks (Fast Profits Daily)
Jan 15, 2021In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Smallcap Stocks: Your Best Bet for 2021 and Beyond (Profit Hunter)
Jan 15, 2021The pandemic failed to thwart Richa's investing success formula for 2020.
Buzzing Sectors Before Budget 2021 (Fast Profits Daily)
Jan 12, 2021The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.
Here's Why Smallcaps Could Be Your Best Investment in 2021 (Profit Hunter)
Jan 12, 2021Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.
More
